Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Crucell has received additional grant of $110m from UNICEF, to supply its paediatric vaccine Quinvaxem to the developing world.
Subscribe to our email newsletter
The latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410m. This is in addition to the $500m obtained over the tender period 2007-2009. They bring the total value of contracts awarded since the launch of Quinvaxem at the end of 2006 to $910m.
Reportedly, during the first tender round in 2006, Crucell was initially awarded $230m (December 2006) and received additional incremental awards of $130m and $140m in May and September 2008, respectively.
Crucell claimed that Quinvaxem is the only fully liquid pentavalent DTwP-HepB-Hib vaccine that is free from the preservative thiomersal. It is an optimal solution for protection against five potentially childhood diseases: diphtheria, tetanus, pertussis, Haemoplilus influenza type b infection and hepatitis B.
Quinvaxem is ready for use without further preparation steps by healthcare workers in the field, which offers major healthcare advantages for these countries with a challenging infrastructure and hygiene problems.